Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL RegistryAnthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
American Journal of Hematology|February 22, 2023
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyScott F Huntington, Stephen J Schuster, Wei Ding, et al.
The Lancet. Haematology|August 30, 2016
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trialPaolo Strati, Mark Lanasa, Timothy G Call, et al.
Plos One|November 10, 2016
Coral Reefs and People in a High-CO2 World: Where Can Science Make a Difference to People?Linwood Pendleton, Adrien Comte, Chris Langdon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
Haematologica|October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M Stephens, Ken Boucher, Elizabeth Kander, et al.
Pageof 10